METHODS: We systematically searched Pubmed, Embase, and Cochrane Library Databases. Two reviewers independently identified relevant random control trials (RCTs) comparing the role of norfloxacin and other antibiotics in SBP prevention.
RESULTS: Eight studies comprising 1043 cirrhotic patients were included in this study. Norfloxacin and alternative antibiotics displayed comparable effects in SBP prophylaxis, survival benefit, overall infection prevention, and safety. Subgroup analyses revealed that rifaximin prophylaxis could reduce the recurrence of SBP with fewer adverse events but failed to improve overall survival compared with norfloxacin.
CONCLUSIONS: Other antibiotics are a reasonable alternative to norfloxacin in the prophylaxis of SBP. Rifaximin prophylaxis could be an alternative choose of antibiotic for SBP prevention because of its better protective effect and safety.
方法:我们系统地搜索了Pubmed,Embase,和Cochrane图书馆数据库。两名评审员独立确定了相关的随机对照试验(RCTs),比较了诺氟沙星和其他抗生素在SBP预防中的作用。
结果:本研究包括8项研究,包括1043例肝硬化患者。诺氟沙星和替代抗生素在SBP预防中表现出可比的效果,生存利益,全面预防感染,和安全。亚组分析显示,与诺氟沙星相比,利福昔明预防可以减少SBP的复发,不良事件较少,但未能改善总生存率。
结论:在预防SBP方面,其他抗生素是诺氟沙星的合理替代品。利福昔明预防具有较好的保护作用和安全性,可作为SBP预防的替代抗生素选择。